| Affiliation: | 1. Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan;2. Department of Premier Preventive Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan;3. Department of Radiology, Osaka City University Graduate School of Medicine, Osaka, Japan;4. Gunze limited, Osaka, Japan;5. Department of Internal Medicine, Division of Diabetes, Endocrinology and Metabolism, Hyogo College of Medicine, Hyogo, Japan;6. Department of Geriatrics and Vascular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan;g Department of Nephrology, Osaka City University Graduate School of Medicine, Osaka, Japan;h Department of Biomedical Engineering, School of Biology-Oriented Science and Technology, Kinki University, Wakayama, Japan;i Department of Immunology, Osaka City University Graduate School of Medicine, Osaka, Japan |
| Abstract: | The clinical success of cell-based therapeutic angiogenesis has been limited in diabetic patients with critical limb ischemia. We previously reported that an injectable cell scaffold (ICS), which is a nano-scaled hydroxyapatite (HAp)-coated polymer microsphere, enhances therapeutic angiogenesis. Subsequently, we developed a modified ICS for clinical use, measuring 50 μm in diameter using poly(l-lactide-co-ε-caprolactone) as a biodegradable polymer, which achieved appropriately accelerated absorption in vivo. The aim of the present study was to evaluate the effectiveness of this practical ICS in diabetic hindlimb ischemia. |
